What is with this bizarre internet obsession with drug repurposing? Let the research work its way through the system before getting hyped on any particular drug for any particular indication. This community is simply not equipped to evaluate the kind of intermediate proposals that researchers make in the literature. You have to watch hundreds of these boom-bust cycles for drugs and targets to get some perspective on what real looks like.
In African continents IVM is over the counter. In accordance to recommended dosing, there seem to be many broadly beneficial effects versus no harmful effects. I just find it more than slightly odd that this cheap commonly available drug was explicitly banned from many (almost all??) western countries.
The list is so incredibly extensive, but here are a few highlights I thought were especially interesting:
> [2.2. Digestive system cancer] Nambara’s study showed that IVM could significantly inhibit the proliferation of gastric cancer cells in vivo and in vitro [....]
> In a study that screened Wnt pathway inhibitors, IVM inhibited the proliferation of multiple cancers, including the colorectal cancer cell lines CC14, CC36, DLD1, and Ls174 T, and promoted apoptosis by blocking the Wnt pathway
> [2.6. Brain glioma]
Glioma is the most common cerebral tumor and approximately 100,000 people worldwide are diagnosed with glioma every year. Glioblastoma is the deadliest glioma, with a median survival time of only 14-17 months. Experiments showed that IVM inhibited the proliferation of human glioblastoma U87 and T98 G cells in a dose-dependent manner and induced apoptosis in a caspase-dependent manner. This was related to the induction of mitochondrial dysfunction and oxidative stress. Moreover, IVM could induce apoptosis of human brain microvascular endothelial cells and significantly inhibit angiogenesis. These results showed that IVM had the potential to resist tumor angiogenesis and tumor metastasis. In another study, IVM inhibited the proliferation of U251 and C6 glioma cells by inhibiting the Akt/mTOR pathway.
> In gliomas, miR-21 can regulate the Ras/MAPK signaling pathway and enhance its effects on proliferation and invasion. The DDX23 helicase activity affects the expression of miR-12. IVM could inhibit the DDX23/miR-12 signaling pathway by affecting the activity of DDX23 helicase, thereby inhibiting malignant biological behaviors. This indicated that IVM may be a potential RNA helicase inhibitor and a new agent for of tumor treatment. However, here, we must emphasize that because IVM cannot effectively pass the blood-brain barrier, the prospect of the use of IVM in the treatment of gliomas is not optimistic.
4 comments
[ 3.2 ms ] story [ 19.8 ms ] threadWhat?
> [2.2. Digestive system cancer] Nambara’s study showed that IVM could significantly inhibit the proliferation of gastric cancer cells in vivo and in vitro [....]
> In a study that screened Wnt pathway inhibitors, IVM inhibited the proliferation of multiple cancers, including the colorectal cancer cell lines CC14, CC36, DLD1, and Ls174 T, and promoted apoptosis by blocking the Wnt pathway
> [2.6. Brain glioma] Glioma is the most common cerebral tumor and approximately 100,000 people worldwide are diagnosed with glioma every year. Glioblastoma is the deadliest glioma, with a median survival time of only 14-17 months. Experiments showed that IVM inhibited the proliferation of human glioblastoma U87 and T98 G cells in a dose-dependent manner and induced apoptosis in a caspase-dependent manner. This was related to the induction of mitochondrial dysfunction and oxidative stress. Moreover, IVM could induce apoptosis of human brain microvascular endothelial cells and significantly inhibit angiogenesis. These results showed that IVM had the potential to resist tumor angiogenesis and tumor metastasis. In another study, IVM inhibited the proliferation of U251 and C6 glioma cells by inhibiting the Akt/mTOR pathway.
> In gliomas, miR-21 can regulate the Ras/MAPK signaling pathway and enhance its effects on proliferation and invasion. The DDX23 helicase activity affects the expression of miR-12. IVM could inhibit the DDX23/miR-12 signaling pathway by affecting the activity of DDX23 helicase, thereby inhibiting malignant biological behaviors. This indicated that IVM may be a potential RNA helicase inhibitor and a new agent for of tumor treatment. However, here, we must emphasize that because IVM cannot effectively pass the blood-brain barrier, the prospect of the use of IVM in the treatment of gliomas is not optimistic.